Novel Therapeutic Approach for Human T-cell Malignancies

Launched by ISTITUTO ONCOLOGICO VENETO IRCCS · Sep 16, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring a new treatment approach for adults with T-cell leukemia and lymphoma, which are types of blood cancers. Researchers are looking for ways to specifically target and eliminate the harmful T-cells by adjusting certain levels within the cells. They will study the effects of different drug combinations, including one that encourages cancer cells to die and another that helps balance cell functions. The goal is to find the most effective treatments that can then be tested on patients whose cancer has not responded to standard treatments.

To participate in this trial, individuals must be over 18 years old and have been diagnosed with T-cell leukemia or lymphoma. Both men and women are eligible, but participants need to be in a condition that allows them to follow standard treatment protocols. If you join the study, you can expect to see how these promising new drugs work on your specific cancer cells in a supportive and monitored environment. This trial is currently recruiting participants, and your involvement could contribute to important advancements in cancer treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with pre- and post-thymic T-cell leukemia/lymphoma
• • Patients of both sexes
• • Age of patients older than 18 years
• • Patient is willing to provide written and signed informed consent for participation in the study
• Exclusion Criteria:
• • -Serious illness or medical condition that does not allow the patient to be managed according to standard treatment protocols, including uncontrolled active infection.